22 results about "Schistosomiases" patented technology

The invention relates to the technical field of medicines, in particular to application of KLB protein in preparation of a medicine for treating schistosome infection. The invention verifies the treatment effect of the KLB protein on hepatic tissue EMT and fibrosis caused by schistosoma japonicum infection, and proves that the KLB can be used as a medicine for treating schistosoma japonicum hepatic fibrosis.

This invention relates to the fields of molecular biology and biomedicine, and discloses siRNA for the expression of the *Schistosoma japonicum* Hsc20 gene and its applications. The siRNA contains a nucleotide sequence that hybridizes to a target sequence of the *Schistosoma japonicum* Hsc20 gene, wherein the target sequence is selected from the sequences shown in SEQ ID NO. 1-SEQ ID NO. 4. The siRNA specifically inhibiting the expression of the *Schistosoma japonicum* Hsc20 gene provided by this invention can be used to interfere with the transcription and expression of the *Schistosoma japonicum* Hsc20 gene and the growth and development of *Schistosoma japonicum*. In vitro experiments have confirmed that the siRNA provided by this invention can efficiently silence the *SjHsc20* gene; and in vivo RNA interference experiments in mice show that this siRNA can induce 50.62% (…) P The insect reduction rate was <0.05% and 44.29% ( P A liver oocyte reduction rate of <0.01% is suitable for preparing drugs to treat schistosomiasis.

The invention discloses a schistosomiasis transmission risk dynamic simulation method based on data fusion and AI, and relates to the technical field of intelligent medical treatment. The method comprises the following steps: firstly, collecting environment, biological media, crowd society and intervention measure multi-source heterogeneous data, and unifying the data to a standard spatio-temporal data cube; then data preprocessing is carried out, and feature variables strongly related to propagation risks are constructed; then the processed data and the characteristic variables are input into a risk simulation engine, the engine adopts a hybrid framework in which a mechanism model and an AI prediction model are deeply fused, a dynamic assimilation algorithm is introduced, and risk level maps of different spatial and temporal scales in the future are output; finally, intervention measure scene simulation is carried out based on the risk level map, the cost-benefit ratio is quantitatively evaluated, and an optimal prevention and control strategy suggestion is generated. According to the method, the hysteresis and static defects of a traditional method are overcome, and real-time sensing, dynamic prediction and intelligent decision support of the schistosomiasis transmission risk are achieved.

This invention relates to the field of biopharmaceutical technology, and more particularly to the application of curcuminoid compounds in the preparation of drugs for treating schistosomiasis, and pharmaceutical compositions thereof. The curcuminoid compounds used in this invention contain different substituents on their benzene rings, which can effectively regulate the electrophilic and lipophilic properties of the compounds, making them easier to enter the schistosomiasis cell. They interact with redox enzymes within the schistosomiasis cell, disrupting the redox balance and promoting schistosomiasis death. Therefore, they exhibit highly effective therapeutic activity against schistosomiasis and show great promise for application in the preparation of drugs for treating schistosomiasis.

The use of a biomarker in the preparation of a diagnostic product and therapeutic drug for Schistosomiasis japonica, wherein the biomarker is uridine or Upase1, which is a key enzyme in uridine metabolism. By means of a large number of studies, changes in metabolites in early and chronic stages of Schistosomiasis japonica infection were analyzed to screen for characteristic metabolites and metabolic pathways. By means of exploring and analyzing abundant region-specific changes of a plurality of metabolites in the liver of mice at different infection stages, it was surprisingly found that Upase1, which is a key enzyme in uridine metabolism, was significantly up-regulated 6 weeks after infection, and the hepatic uridine level was negatively correlated with the abundance of a plurality of lipid-related metabolites. Moreover, verification, and specificity and sensitivity studies confirmed that uridine or Upase1, which is a key enzyme in uridine metabolism, could be used as a characteristic marker molecule for Schistosomiasis japonica infection, and for developing diagnostic products for Schistosomiasis japonica. Further studies have found that in vitro supplementation with uridine can exert an anti-fibrotic role, and uridine can be used as a therapeutic drug for Schistosomiasis japonica.

The invention provides a monoclonal antibody aiming at schistosoma japonicum SPRM1hc protein and application of the monoclonal antibody, and belongs to the technical fields of parasite infection treatment, biological medicine, immunotherapy and in-vitro diagnosis. The invention provides two monoclonal antibodies A028 and A032 which can be specifically combined with the extracellular domain of SPRM1hc protein, the actual effect of the monoclonal antibodies A028 and A032 in treatment of schistosoma japonicum katsurada after infection is verified, and the monoclonal antibodies A028 and A032 have a remarkable treatment effect in an infected animal model, and can reduce polypide load, reduce egg deposition and improve tissue pathological damage. The application of the monoclonal antibody to preparation of drugs for resisting schistosoma japonicum katsurada infection and development of schistosoma japonicum katsurada antigen detection kits has very important practical significance.

The invention relates to application of aspirin in preparation of an anti-schistosoma japonicum medicine, and in the invention, by applying a schistosoma japonicum infection mouse model, the treatment effect of aspirin on schistosoma japonicum is found. Specifically, the aspirin can significantly reduce the number of insect bodies infected in mice and the number of eggs deposited in livers, and can effectively inhibit the antigen secretion ability of the eggs infected in the livers of the mice, the granuloma inflammation induced by the eggs and the hepatic fibrosis degree, so that the aspirin can be applied to treatment of schistosoma japonicum katsurada. And a new application of aspirin is added clinically. As a non-steroidal anti-inflammatory drug, aspirin is widely applied clinically, has the advantages of safety, reliability, stability, low cost, easiness in obtaining and the like, and is relatively deep in pharmacological research and relatively clear in action mechanism. Therefore, the scheme of the invention is suitable for clinical popularization and use.

The utility model discloses a three-in-one tweezers relates to the field of schistosomiasis prevention and cure. The tool includes tweezers, and the tweezers tail end is connected with two tweezers arms through connecting shaft, and the connecting shaft is rotatably connected with sleeve with hammer handle, and the connecting shaft is equipped with limiting stopper to limit sleeve corner, and the hammer handle bottom end is fixed with hammer head, and the tweezers front end is equipped with telescopic steel needle, and the steel needle tip can extend or retract, and the front end is equipped with fastening knob to lock steel needle. The connecting shaft is composed of detachable left and right half shafts, is fastened through positioning plug, insertion slot and connecting screw, and is equipped with damping between sleeve and half shaft to make hammer handle can hover at will. The tool integrates clamping, crushing and picking functions, does not need to frequently change tools, and effectively improves detection snail efficiency.

The invention discloses application of 5HTR1 and Sj5HTR1 gene segments, dsRNA for interfering schistosome and application of the dsRNA, the nucleotide sequence of a sense strand of the dsRNA is as shown in SEQ ID NO.1, the nucleotide sequence of an antisense strand of the dsRNA is as shown in SEQ ID NO.2, and the dsRNA can be applied to preparation of anti-schistosomiasis drugs. The dsRNA is targeted to a 5-hydroxytryptamine receptor 1, development and survival of schistosome and oviposition of female schistosome can be remarkably inhibited, damage of schistosome to host pathology can be effectively reduced, and it is also shown that Sj5HTR1 is a potential anti-schistosome treatment target and plays an important role in schistosome biology.

The invention relates to a double-stranded ribonucleic acid composition for targeted inhibition of SjHAT1 expression and application of the double-stranded ribonucleic acid composition, and relates to the technical field of biological medicines. The method comprises the following steps: firstly, acquiring a full-length cDNA sequence of SjHAT1 by utilizing a cDNA terminal rapid amplification (RACE) technology in early-stage work, and accurately positioning a transcription condition and a distribution condition of the SjHAT1 gene in schistosoma japonicum adults by utilizing the acquired full-length cDNA sequence. Furthermore, according to the full-length cDNA sequence of the SjHAT1, the dsRNA composition for knocking down the SjHAT1 in a targeted mode is designed, the dsRNA composition can efficiently knock down the SjHAT1, the interference effect is good, the validity period is long, the treatment effect is better than that of a targeted drug DW-3-15, the dsRNA composition shows a good action effect in both in-vivo and in-vitro experiments, and the dsRNA composition has good application prospects. Wide application prospects are realized in the aspects of treatment of schistosomiasis, preparation of insecticides and the like.

The invention relates to an oral mRNA vaccine delivery system aiming at schistosoma japonicum katsurada parasite protecting hosts. The invention discloses an oral mRNA vaccine based on a bacillus subtilis spore delivery system for schistosoma japonicum parasite protection hosts, which has the characteristics of simplicity and convenience in preparation, friendly inoculation mode, good immune effect and the like, and is particularly suitable for large-scale immunization of the schistosoma japonicum parasite protection hosts such as cattle, sheep and the like so as to block the propagation of schistosoma japonicum from the source. The invention not only provides powerful scientific and technological support for achieving the goal of eliminating schistosomiasis in Healthy China 2030, but also greatly spans and innovates on the existing oral bacterial carrier technology.

The application belongs to the technical field of biological medicine, and relates to application of mucinophilic Akkermansia or outer vesicles thereof in preparation of a schistosomiasis treatment drug. The application enhances host anti-infection immunity by regulating intestinal flora balance (restoring diversity and composition), improving immune response (regulating macrophages, CD8+ T cell recruitment and Th1 / Th2 balance), improving intestinal barrier function, reducing pathogen invasion and inflammation, significantly reducing liver granuloma and liver fibrosis caused by schistosome infection, and improving liver function. The application reveals the key role of MIF gene in immune regulation, and provides a new direction for schistosomiasis immunotherapy. In addition, the probiotic treatment has high safety, no obvious side effects, can be combined with chemotherapy, enhances the curative effect, reduces the side effects of chemical drugs and drug resistance, provides a persistent and comprehensive adjuvant treatment scheme for schistosomiasis, and has important clinical application potential.

Provided herein are aryl hydantoin compounds having the structure of Formula (I) wherein X, R1, R2, R3, R4, and n are described herein. Also provided herein are compositions comprising compounds of Formula (I) and methods of using compounds of Formula (I) in treating, inhibiting, and / or preventing a parasitic disease (e.g., Schistosomiasis).

This invention discloses an AI-assisted intelligent schistosomiasis control information monitoring, early warning, and management method and system, relating to the field of deep learning technology. The method includes: acquiring multi-source monitoring data through an intelligent data acquisition terminal network; constructing a multimodal spatiotemporal knowledge graph and a multi-timescale feature library; constructing a deep temporal network with enhanced spatiotemporal attention based on the multimodal spatiotemporal knowledge graph to capture the spatiotemporal evolution pattern of media propagation and generate predicted infection numbers for each grid unit; extracting historical weather features and infection number sequences from the multi-timescale feature library, calculating weighted baseline values ​​for weather-similar days and moving percentile anomaly reference values, and fusing them into a dynamic early warning baseline. This invention significantly improves prediction accuracy and interpretability in data-sparse areas by capturing key historical fragments through an attention mechanism in the temporal dimension and aggregating neighborhood propagation information through a graph structure in the spatial dimension.

The invention provides a covalent small molecule compound and application and a pharmaceutical composition thereof, and relates to the technical field of pharmaceutical chemistry. The covalent small molecule compound provided by the invention can be combined with specific amino acid in the schistosome to form a covalent bond so as to inhibit the biological function of the schistosome. The covalent small molecule compound provided by the invention has a good killing effect on schistosomiasis and adult schistosomiasis, can be used for preparing drugs for treating schistosomiasis, and overcomes the technical problem of poor curative effect or ineffective treatment caused by drug resistance generated by long-term use of existing anti-schistosomiasis drugs; important scientific basis and research value are provided for research and development of novel anti-schistosomiasis drugs. The result of the embodiment shows that the insect reduction rate of the covalent small molecule compound provided by the invention can reach 82.35% (superior to praziquantel) in the juvenile insect stage, the insect reduction rate of the covalent small molecule compound in the adult stage can reach 63.63%, and the covalent small molecule compound shows relatively high activity of killing schistosome in vivo.

The application relates to the technical field of intelligent medical treatment, and discloses a schistosomiasis laboratory quality management remote consultation system and method based on artificial intelligence. The application effectively solves the problems of weak network transmission congestion, long tail impurity misjudgment and system failure caused by environmental drift that the primary medical institutions face when performing schistosomiasis remote consultation, accurately extracts primary lesion features by dynamically perceiving local optical density changes on the edge side, and under the limited network communication bandwidth, preferentially guarantees high-fidelity lossless push flow of core lesion features, simultaneously implements adaptive degradation and physical truncation on redundant background features, and combines a local cache mechanism to completely eliminate feature space tearing and diagnostic data loss under extremely deteriorated communication environment.

The present application belongs to the field of molecular biology detection, and particularly relates to detection of blood flukes, and more particularly to the use of SjTR1 microsatellite sequence for preparing reagents for detecting blood fluke disease. The present application provides the use of SjTR1 microsatellite sequence of Schistosoma japonicum for preparing reagents for detecting blood fluke disease. The PCR detection reagent prepared by using the new target point discovered by the present application can obtain higher sensitivity and specificity compared with the existing target point of Schistosoma japonicum, such as SJR2. In particular, in the design process of multiplex PCR, the new target point can make the whole system obtain better sensitivity and better specificity.

The invention relates to the technical field of medicines, in particular to application of KLB protein in preparation of a medicine for treating schistosome infection. The invention verifies the treatment effect of the KLB protein on hepatic tissue EMT and fibrosis caused by schistosoma japonicum infection, and proves that the KLB can be used as a medicine for treating schistosoma japonicum hepatic fibrosis.

The invention discloses a snail suppression ecological revetment design method and system based on schistosomiasis transmission risk grading, computer equipment and a storage medium. The design method comprises the steps that river reach division is carried out in the flow direction of a river channel, and ecological environment data of each river reach under different hydro-meteorological conditions are obtained; based on the ecological environment data, calculating a comprehensive index of the schistosomiasis transmission risk of each river reach under different hydro-meteorological conditions; dividing each river reach into a low-risk river reach or a high-risk river reach according to the comprehensive index; and matching river bank construction schemes corresponding to the risky river reaches of different grades. According to the technical scheme, accurate recognition of the oncomelania breeding place is achieved, the river reach is divided into the high-risk river reach and the low-risk river reach, then key prevention and control measures are adopted for the high-risk river reach, and relatively mild ecological protection measures are adopted for the low-risk river reach. In this way, precise prevention and control of different risk areas are achieved, excessive intervention on an ecological system is reduced, and collaborative improvement of the snail suppression efficiency and ecological benefits is achieved.

The application discloses a liver fibrosis detection grading model construction method applied to schistosomiasis, relates to the technical field of medical detection, collects multi-modal liver sample data for standardized processing to generate standard multi-modal data, adopts corresponding processing methods for feature processing on different standard multi-modal data, obtains liver image features, serum biochemical marker features and pathological section features representing the influence of schistosomiasis on liver fibrosis, constructs a multi-modal joint grading diagnosis model based on the features to detect liver fibrosis of patients with schistosomiasis, verifies the detection result of the liver fibrosis detection, dynamically optimizes the multi-modal joint grading diagnosis model based on the detection result, evaluates the model indication of the multi-modal joint grading diagnosis model after the dynamic optimization is completed, and determines whether to adjust the optimization parameter of the dynamic optimization of the multi-modal joint grading diagnosis model based on the model indication.

The invention belongs to the technical field of bioengineering, and relates to schistosoma japonicum recombinant antigens rSjCB1 and rSjSAP4 and application thereof. The schistosoma japonicum recombinant antigen rSjCB1 is used as a detection antigen for schistosomiasis diagnosis, has sensitivity of 97.87% and specificity of 81% on sheep schistosoma japonicum, and has no cross reaction with sheep serum infected by pichia pastoris and haemonchus contortus. The combined detection result of the rSjCB1 and the rSjSAP4 shows that the sensitivity is 93.62%, and the specificity is 92%, so that the recombinant antigen rSjCB1, the rSjCB1 and the rSjSAP4 prepared by the invention are used for diagnosing the sheep schistosomiasis, are high in sensitivity and strong in specificity, and have important significance in preventing and treating the sheep schistosomiasis.

The invention relates to the field of molecular biology and biological medicine, and discloses a schistosoma japonicum Hsc20 gene expressed siRNA and application thereof, the siRNA contains a nucleotide sequence hybridized with a target sequence of the schistosoma japonicum Hsc20 gene, and the target sequence is selected from sequences shown as SEQ ID NO.1-SEQ ID NO.4. The invention also discloses a preparation method of the schistosoma japonicum Hsc20 gene expressed siRNA. The siRNA for specifically inhibiting the expression of the schistosoma japonicum Hsc20 gene, provided by the invention, can be used for interfering the transcription and expression of the schistosoma japonicum Hsc20 gene and the growth and development of schistosoma japonicum; in-vitro experiments prove that the siRNA provided by the invention can be used for efficiently silencing the SjHsc20 gene; in-vivo RNA interference test results of mice show that the siRNA can induce the mice to obtain 50.62% (Plt; 0.05) and an insect reduction rate of 44.29% (Plt; 0.01), and is suitable for preparing the medicine for treating the schistosomiasis.